commonly in dogs, with its frequency and effects on prognosis not previously reported. 1 Melphalan is a cell cycle phase-nonspecific alkylating agent, often given in combination with prednisone to treat dogs with MM.
1,2 A therapeutic regimen of daily melphalan and prednisone was associated with a median survival time of 540 days and overall response rate of 92%. 2 An alternative, pulse dose schedule also has been used to treat dogs with MM, 1 Hypercalcemia, osteolytic lesions, and Bence-Jones proteinuria were reported to be negative prognostic factors for MM in dogs. 2 Nonazotemic dogs also had a longer survival compared with azotemic dogs, but this difference was not statistically significant. 2 In contrast, studies of MM in humans have not consistently found hypercalcemia, osteolytic lesions, and Bence-Jones proteinuria to be prognostic, 7, 8 and instead use risk stratification models that primarily rely on cytogenetics, gene expression profiling, the International Staging System, and serum lactate dehydrogenase activity as prognostic markers. [9] [10] [11] Other studies have evaluated factors such as renal disease, 7, 8, [12] [13] [14] [15] [16] [17] [18] neutrophil-tolymphocyte ratio (NLR), [19] [20] [21] [22] [23] [24] platelet-to-lymphocyte ratio (PLR), 23, 24 and anemia, [25] [26] [27] which have negatively affected outcome. Several studies in veterinary oncology have evaluated NLR as a prognostic factor in dog, [28] [29] [30] [31] but no studies, to the authors' knowledge, have evaluated NLR or PLR in dogs with MM. Additionally, factors such as anemia, neutropenia, thrombocytopenia, and abdominal involvement, have not been specifically evaluated for prognostic relevance in dogs with MM.
The primary objective of our study was to compare outcome and adverse event profiles between pulse dose and daily dose melphalan protocols in dogs with MM. Our secondary objective was to report prognostic factors. We hypothesized that both melphalan-based protocols would be associated with similar outcomes and be tolerated well.
| M A TE RI A L A ND M E TH ODS

| Study design
Retrospective cohort study performed at the School of Veterinary
Medicine at the University of Wisconsin-Madison.
| Cohort identification
A search of medical records of dogs diagnosed with MM that had received melphalan at the University of Wisconsin-Madison Veterinary
Care Hospital between January 1998 and April 2016 was performed.
Additional cases were contributed by other veterinary medical oncologists during the same time period in response to a call posted on the ACVIM listserve. Dogs were included in the study if they were diagnosed with MM and received PO melphalan, either pulse dose or daily dose. A diagnosis of MM was reached based on evidence of 2 of the following criteria: bone marrow plasmacytosis, osteolytic lesions, other organ involvement, and presence of myeloma proteins in blood or urine. Categories for presenting clinical signs and clinicopathologic abnormalities (based on the performed diagnostic tests) are described in Table 1 .
All dogs with renal disease had resolution of azotemia after initiation of treatment, and their renal disease was retrospectively graded (solely by serum creatinine concentration) according to International Renal Interest Society (IRIS) guidelines for acute kidney injury (AKI). [32] [33] [34] [35] Outcome was reported as: overall survival time (OST), defined as the interval from diagnosis to death; progression-free survival (PFS), defined as the interval from treatment initiation to onset of PD; disease-free interval (DFI), defined as the interval from a CR to relapse; survival from remission (SFR), defined as the interval from a CR until death; and, time to remission (TR), defined as the interval from treatment initiation to a CR. Dogs that died of a cause other than MM, were lost to follow-up or were still alive at the end of data collection were censored. Dogs that remained alive at the end of data collection were censored as of the last date they were reported to be alive.
The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. The PLR was defined as the platelet count divided by the absolute lymphocyte count. 24 All laboratory variables used to calculate NLR and PLR were obtained within 4 weeks before or after the diagnosis of MM, in accordance with a study of humans with MM. 24 A contemporaneous control group was randomly selected from hospital dogs and used for the receiver operating characteristic (ROC) curve. 24 Exclusion criteria for the control group included the following: acute or chronic infections, acute or chronic liver disease, other concomitant malignancies, thrombocytopenia, inflammationpromoting diseases (eg, osteoarthritis, colitis), or dogs receiving antiinflammatory medications for >2 weeks.
Overall response rate and biologic response rate were evaluated using an adaptation of the International Uniform Response Criteria for MM 36 in the majority of cases; in 2 dogs responses were determined from radiographic changes (ie, osteolytic lesions). Survival rates were calculated using the indirect method as previously described. 37 
| Statistical analysis
All statistical analyses were performed using commercial statistical soft- 
| Clinical and clinicopathologic findings
The presenting clinical and clinicopathologic findings are summarized in Table 1 . Concurrent malignancies are summarized in Table 2 .
| Diagnostic imaging
Abdominal ultrasound examination was performed at the time of diagnosis in 28 dogs. Sixteen dogs (57%) had cytologically confirmed abdominal involvement (Table 1) 
| Adverse events
Both treatment protocols were well tolerated. Thrombocytopenia was the most common adverse event in both cohorts. The highest grade of thrombocytopenia reported while receiving therapy is presented in Table 3 . Aside from 1 dog with grade 1 thrombocytopenia receiving 10 months of daily melphalan therapy that was euthanized for progressive MM, all other grade 1 and 2 thrombocytopenic events did not result in dose reductions, dose delays, or discontinuation of melphalan therapy.
Neutropenia and anemia were common and low-grade in both cohorts. The daily dose melphalan cohort had one grade 1 neutropenic event and seven grade 1 and one grade 2 anemic events. The pulse dose melphalan protocol had one grade 1, two grade 2, and two grade 3 neutropenic events and six grade 1 anemic events.
No adverse gastrointestinal effects were reported.
| Outcome
Response and outcome data are summarized in Table 4 . Of the 38 dogs Twenty-four dogs were censored from the OST analysis ( Figure 1); 14, 21, 26, and 10 dogs were censored from the PFS, DFI, SFR, and TR analyses, respectively. No significant differences were found between the treatment cohorts for any of the outcome variables.
| Treatment at relapse
Three dogs (8%) initially were treated with the daily dose protocol and later were switched to the pulse dose protocol. One of these dogs achieved SD after starting daily dose melphalan. Eighty-five days later, PD was noted and this dog was switched to pulse dose melphalan. The pulse dose regimen resulted in a CR, which was sustained for 1481 days. Pulse dose melphalan was discontinued thereafter, and this dog continued to be free of MM or any myelosuppressive effects at the end of the follow-up period. The second dog achieved a CR with daily dose melphalan for 258 days, at which time PD was noted and pulse dose melphalan was initiated. This dog maintained SD with the pulse dose regimen for 190 days, after which time a single dose of lomustine was given and no subsequent treatment was pursued. The third dog maintained SD for 70 days on daily dose treatment, after which pulse dose treatment was initiated. This dog maintained SD for 48 days, at which time progression was noted and lomustine was given as rescue treatment. All 3 dogs were included in the daily dose cohort for analysis, 
| NLR and PLR
Twenty-six dogs (68%) were included in the NLR and PLR analyses because only these dogs had complete CBCs available for review within 4 weeks of diagnosis. The remaining 12 dogs (32%) had CBCs performed and reported to be unremarkable. Hence, specific results were not reported, and these dogs therefore were not included in the NLR and PLR analyses. The median NLR was 4.03 (range, 1.58-28.67), and the median PLR was 146.70 (range, 
| Prognostic factors
Significant prognostic factors are summarized in Table 5 . Both renal disease ( Figure 2 ) and NLR ( Figure 3 ) were significantly prognostic for OST, PFS, and DFI. The NLR alone was significantly prognostic for SFR.
None of the other factors held any prognostic significance with respect to OST, PFS, DFI, SFR, and TR.
| D I SCUSSION
To the authors' knowledge, ours is the first study to evaluate pulse dose melphalan and compare it to daily dose melphalan in dogs with MM. Our hypothesis was supported by the lack of significant difference in outcome and adverse event profiles between the pulse and daily dosing regimens, although small cohort size and high numbers of censored dogs could have impacted this result. Both protocols were associated with high response rates, a short TR and few dose-limiting adverse events. Previously reported negative prognostic factors including hypercalcemia and osteolytic lesions were not confirmed in our study, whereas renal disease and high NLR emerged as potential negative prognostic indicators.
Melphalan chemotherapy typically is well tolerated, with myelosuppression being the most common dose-limiting toxicity. In our study, renal disease was found to be significantly associated with shorter OST, PFS, and DFI. This finding is corroborated by studies in human patients with newly diagnosed MM, 7, 8, 12, 14, 17, 18, 43, 47 with some studies relating prognosis to the severity of renal impairment 14 and others showing a correlation between reversibility of renal impairment and improved overall survival. 8, 47 Other studies however refute the role of kidney disease as an independent prognostic factor when adjusted for MM stage. 16, 48 All dogs in our study had reversible azote- was not associated with prognosis in our study.
Limitations of our study are attributable to its retrospective nature and include the lack of randomization as well as lack of standardization in staging tests, follow-up, response evaluation, and rescue treatment.
Our study also included a relatively small sample size, which may be attributable to the relative rarity of MM in dogs. In conclusion, our findings suggest that dogs with MM being treated with melphalan in either the daily or pulse dose setting have a favorable prognosis with minimal chemotherapy-related toxicity. Renal disease and high NLR were found to be independent negative prognostic factors in our study population.
Prospective, controlled, and randomized studies to confirm these results are warranted.
